| 44.15 0 (0%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 51.96 | 1-year : | 52.82 |
| Resists | First : | 44.49 | Second : | 45.22 |
| Pivot price | 44.04 |
|||
| Supports | First : | 43.3 | Second : | 36.02 |
| MAs | MA(5) : | 44.18 |
MA(20) : | 44.18 |
| MA(100) : | 29.73 |
MA(250) : | 26.39 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 68.5 |
D(3) : | 64.2 |
| RSI | RSI(14): 68 |
|||
| 52-week | High : | 45.22 | Low : | 16.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALBO ] has closed below upper band by 42.0%. Bollinger Bands are 84.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 44.78 - 45 | 45 - 45.15 |
| Low: | 43.41 - 43.71 | 43.71 - 43.9 |
| Close: | 43.82 - 44.27 | 44.27 - 44.56 |
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Mon, 22 Apr 2024
How Many Albireo Pharma, Inc. (NASDAQ:ALBO) Shares Do Institutions Own? - Yahoo Movies Canada
Thu, 02 Mar 2023
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio - Ipsen
Thu, 02 Feb 2023
Buyout From Ipsen: Do Not Underestimate Value Of Albireo's Contingent Value Right - Seeking Alpha
Mon, 09 Jan 2023
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline - Yahoo Finance
Mon, 09 Jan 2023
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases - Ipsen
Wed, 12 Oct 2022
Albireo: Strong Phase 3 Data Foretells More Upside (NASDAQ:ALBO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 107.6 (%) |
| Shares Short | 554 (K) |
| Shares Short P.Month | 823 (K) |
| EPS | -6.66 |
| EPS Est Next Qtrly | -0.92 |
| EPS Est This Year | -3.65 |
| EPS Est Next Year | -3.45 |
| Book Value (p.s.) | 4.84 |
| Profit Margin | -228.6 % |
| Operating Margin | -214.8 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -93.1 % |
| Qtrly Rev. Growth | 168.3 % |
| Gross Profit (p.s.) | 1.89 |
| Sales Per Share | 2.76 |
| EBITDA (p.s.) | -5.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -74 (M) |
| PE Ratio | -6.63 |
| PEG Ratio | 0 |
| Price to Book value | 9.12 |
| Price to Sales | 15.95 |
| Price to Cash Flow | -7.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2016-11-03 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|